Stay Connected

  • This field is for validation purposes and should be left unchanged.

Together, We Create Real Impact

3 Legislative wins in 2012 Over 30M Raised 5 FDA treatments approved

From the Blog

  • February 28, 2017

    Lighting Up Like Fireworks: A First-Person Brain Tumor Journey Captures Headlines


    Today is “Rare Disease Day” in America. Brain tumors are technically categorized as a rare disease, though at National Brain Tumor Society we like to say, “it’s the rare disease that eve

    Read More

  • February 27, 2017

    Brain Tumor Research Highlights: February 2017


    See January 2017’s Brain Tumor Research Highlights here. Over the years, NBTS has given more than $35 million to brain tumor research projects. We’re very proud of the impact this funding has made i

    Read More

  • February 23, 2017

    National Brain Tumor Society Statement on Tocagen Designation

    Today, Tocagen, a company developing a gene therapy to treat cancer, announced that it has received “Breakthrough Therapy Designation*” for its lead product candidate Toca 511 & Toca FC** from the U.S. Food and Drug Administration (FDA) for the treatment of recurrent high-grade glioma (glioblastomas and anaplastic astrocytomas). Tocagen was granted Breakthrough Therapy Designation based [

    Read More

More from the blog